Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 1, 2009

Complete Genomics and GATC Ally on Human Genome Sequencing Projects

  • GATC Biotech and Complete Genomics have entered a research agreement to sequence human genomes from GATC samples. The aim is to provide scientists with relevant genomic details to advance the understanding of the genetic causes of disease.

    A pilot project has begun with Complete Genomics sequencing and assembling the genomes. The firm will then provide GATC with detected variants including SNPs and indels. Finally GATC will perform additional bioinformatics analysis such as comparison of the variant data of different genomes.

    “GATC aims to continually offer our customers the most innovative, efficient, and integrated sequencing technologies and applications for their research projects,” states Peter Pohl, CEO of GATC Biotech. “To achieve our 100-Human-Genome-Project goal, evaluating Complete Genomics’ human genome sequencing technology is a logical step.”

    Complete Genomics’ sequencing platform combines technology advancements in libraries, arrays, sequencing assay chemistry, instruments, and software. The low reagent usage and high imaging efficiency enables sequencing of complete human genomes at a fraction of the cost of alternative approaches, according to the company.

    Additionally, the accuracy of its sequencing chemistry combined with custom mapping and assembly techniques enable the sequencing process to resolve many of the complexities of the human genome, the company adds.



GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »